Use of nepafenac (Nevanac®)in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 1249-1252

  Chen, Eric ^a   Benz, Matthew S ^a   Fish, Richard H ^a   Brown, David M ^a   Wong, Tien P ^a   Kim, Rosa Y ^a   Major, James C ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Anti VEGF; Combination therapy; Exudative macular degeneration; Nonsteroidal anti inflammatory; Optical coherence tomography

Indexed keywords

BEVACIZUMAB; NEPAFENAC; RANIBIZUMAB; VASCULOTROPIN ANTIBODY;

AGED; CASE STUDY; CLINICAL ARTICLE; CLINICAL EXAMINATION; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; EXUDATIVE MACULAR DEGENERATION; FEMALE; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MALE; OPTICAL COHERENCE TOMOGRAPHY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RETINA DETACHMENT; RETINA FOVEA; RETROSPECTIVE STUDY; REVIEW; SUBRETINAL FLUID; VISUAL ACUITY;

EID: 78650683541     PISSN: 11775467     EISSN: 11775483     Source Type: Book Series    
DOI: 10.2147/OPTH.S14092     Document Type: Review

References (18)

1. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004; 122(4):564-572.
2. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol. 2004;122(4):598-614.
3. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18(1):4-25.
4. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
5. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14): 1419-1431.
6. Augustin AJ, Kirchhof J. Inflammation and the pathogenesis of agerelated macular degeneration. Expert Opin Ther Targets. 2009;13(6): 641-651.
7. Grant CA. Combination therapy: lucentis (ranibizumab injection) and xibrom (bromfenac ophthalmic solution) 0.09% in the treatment of choroidal neovascular membrane secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49 (E-Abstract 563).
8. Lindstrom R, Kim T. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. Curr Med Res Opin. 2006;22(2):397-404.
9. Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol. 2007; 144(4):627-637.
10. Regillo CD, Brown DM, Abraham P, et al. Randomized, double- masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008; 145(2):239-248.
11. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148(1):43-58 e41.
12. Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol. 2010;21(3):178-183.
13. Shah GK, Sang DN, Hughes MS. Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration. Retina. 2009;29(2):133-148.
14. Zweifel SA, Engelbert M, Khan S, Freund KB. Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration. Retina. 2009;29(10):1527-1531.
15. Walters T, Raizman M, Ernest P, Gayton J, Lehmann R. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007;33(9): 1539-1545.
16. Takahashi K, Saishin Y, Saishin Y, et al. Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci. 2003;44(1): 409-415.
17. Yanni SE, Clark ML, Yang R, Bingaman DP, Penn JS. The effects of nepafenac and amfenac on retinal angiogenesis. Brain Res Bull. 2010; 81(2-3):310-319.
18. Libondi T, Jonas JB. Topical nepafenac for treatment of exudative age- related macular degeneration. Acta Ophthalmol. 2010;88(2): e32-e33.